G. Lo Russo

117P Predicting immunotherapy response in non-small cell lung cancer using a foundation model for tabular data and real-world clinical evidence: Insights from APOLLO11 study

Concetta Licciardello, A. Ferrarin, O. Sidelnikova, Laura Mazzeo et autres

it (code pays fourni par la source)

P1.11.01 First-Line Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metastatic NSCLC: Real World Data in Italy

F. Agustoni, G Gambini, G. Lo Russo, C. Proto et autres

it, ca, us (code pays fourni par la source)

Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer

L. Provenzano, M. A. Favali, L. Mazzeo, A. Spagnoletti et autres

it, us (code pays fourni par la source)

26P: Assessing first-line immunotherapy duration in advanced NSCLC

Simone Rota, R. Serino, P. Ambrosini, T. Beninato et autres

131TiP: TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C

Margarita Majem, K.J. O’Byrne, G. Lo Russo, Christian Mueller et autres

es, au, it, de (code pays fourni par la source)

25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils

Roberto Ferrara, G. Lo Russo, C.M. Ciniselli, B. Bassani et autres

it, us (code pays fourni par la source)